KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Other Operating Expenses (2017 - 2025)

Aquestive Therapeutics has reported Other Operating Expenses over the past 9 years, most recently at $5.8 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at $5.8 million for Q4 2025, up 29.12% from a year ago — trailing twelve months through Dec 2025 was $18.6 million (up 3.82% YoY), and the annual figure for FY2025 was $18.6 million, up 3.82%.
  • Other Operating Expenses for Q4 2025 was $5.8 million at Aquestive Therapeutics, up from $4.5 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for AQST hit a ceiling of $6.6 million in Q2 2023 and a floor of $2.8 million in Q1 2021.
  • Median Other Operating Expenses over the past 5 years was $4.5 million (2024), compared with a mean of $4.6 million.
  • Biggest five-year swings in Other Operating Expenses: skyrocketed 57.61% in 2022 and later crashed 31.6% in 2024.
  • Aquestive Therapeutics' Other Operating Expenses stood at $3.4 million in 2021, then skyrocketed by 57.61% to $5.3 million in 2022, then fell by 11.8% to $4.7 million in 2023, then fell by 3.4% to $4.5 million in 2024, then rose by 29.12% to $5.8 million in 2025.
  • The last three reported values for Other Operating Expenses were $5.8 million (Q4 2025), $4.5 million (Q3 2025), and $4.6 million (Q2 2025) per Business Quant data.